The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment
The DOI matches its Crossref record, with a small difference in title or year; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The chylomicronemia syndrome occurs when triglyceride levels are severely elevated (usually >16.95 mmol/L [1500 mg/dL]) and is characterized by such clinical features as abdominal pain, acute pancreatitis, eruptive xanthomas, and lipemia retinalis. It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyceridemia, termed multifactorial chylomicronemia syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, termed familial chylomicronemia syndrome (FCS); or familial partial lipodystrophy. Most chylomicronemia syndrome cases are the result of MFCS; FCS is very rare. In all these conditions, triglyceride-rich lipoproteins accumulate because of impaired plasma clearance. This review describes the 3 major causes of the chylomicronemia syndrome; their consequences; and the approaches to treatment, which differ considerably by group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multifactorial chylomicronemia syndrome is the most common of the 3 conditions that elevate triglycerides levels high enough to provoke the characteristic clinical features of excess chylomicronemia, which include lipemia retinalis, eruptive xanthomas, abdominal pain, and hyperlipidemic pancreatitis (42).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [42]
In the citing paper
“Clearance of triglycerides from plasma is saturable when plasma triglyceride levels exceed approximately 500 to 700 mg/dL and further input of chylomicrons and VLDL into plasma cannot readily be removed, leading to marked hypertriglyceridemia and chylomicronemia, even after an overnight fast (42).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [42]
In the citing paper
“Lipoprotein lipase-mediated lipolysis of newly secreted TRLs is a saturable process, and as secretion rates and plasma TG levels rise, lipolysis falls.14”
From Clinical review on triglycerides (2020) · cites this paper as [14]
In the citing paper
“However, pancreatitis risk is highest in rare patients with monogenic chylomicronaemia, in which chylomicrons are indeed the predominant species, with low to undetectable levels of remnants and downstream lipoproteins due to severely impaired lipolytic machinery.6,14,29,30”
From Clinical review on triglycerides (2020) · cites this paper as [14]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Prognostic signs and the role of operative management in acute pancreatitis.
Ranson, J. H. C., Rifkind, K., Roses, D. F., Fink, S. D., Eng, K., & Spencer, F. C. (1974) · PubMed · Cited by 1,347
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Lipodystrophies: Genetic and Acquired Body Fat Disorders
Garg, A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1159 · Cited by 557
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701122760206 · Cited by 499
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Brunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484
DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene
Nickerson, D. A., Taylor, S. L., Weiss, K. M., Clark, A. G., Hutchinson, R. G., Stengård, J., Salomaa, V., Vartiainen, E., Boerwinkle, E., & Sing, C. F. (1998) · Nature Genetics · doi:10.1038/907 · Cited by 476
ANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
(1995) · PubMed · Cited by 423
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
IDIOPATHIC HYPERLIPEMIA: METABOLIC STUDIES IN AN AFFECTED FAMILY*
Havel, R. J., & Gordon, R. S. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104202 · Cited by 380
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
van der Vliet, H. N., Sammels, M. G., Leegwater, A. C. J., Levels, J. H. M., Reitsma, P. H., Boers, W., & Chamuleau, R. A. F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106888200 · Cited by 344
Nordestgaard, B. G., Wootton, R., & Lewis, B. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.534 · Cited by 334
Benlian, P., De Gennes, J. L., Foubert, L., Zhang, H., Gagné, S. E., & Hayden, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351203 · Cited by 297
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274
Safety considerations with niacin therapy
Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.018 · Cited by 269
Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia
Surendran, R. P., Visser, M. E., Heemelaar, S., Wang, J., Peter, J., Defesche, J. C., Kuivenhoven, J. A., Hosseini, M., Péterfy, M., Kastelein, J. J. P., et al. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02516.x · Cited by 249
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Ford, E. S., Li, C., Zhao, G., Pearson, W. S., & Mokdad, A. H. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.599 · Cited by 214
The changing character of acute pancreatitis: Epidemiology, etiology, and prognosis
Lowenfels, A. B., Maisonneuve, P., & Sullivan, T. (2009) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0016-4 · Cited by 210
Hussain, I., & Garg, A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.012 · Cited by 200
ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance
Haller, J. F., Mintah, I. J., Shihanian, L. M., Stevis, P., Buckler, D., Alexa-Braun, C. A., Kleiner, S., Banfi, S., Cohen, J. C., Hobbs, H. H., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075689 · Cited by 199
Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia
Oliva, C. P., Pisciotta, L., Volti, G. L., Sambataro, M. P., Cantafora, A., Bellocchio, A., Catapano, A., Tarugi, P., Bertolini, S., & Calandra, S. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000153087.36428.dd · Cited by 187
Diker-Cohen, T., Cochran, E., Gorden, P., & Brown, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4491 · Cited by 178
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Chi, X., Britt, E. C., Shows, H. W., Hjelmaas, A. J., Shetty, S. K., Cushing, E. M., Li, W., Dou, A., Zhang, R., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.014 · Cited by 174
Carpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165
Wilson, D. E., Emi, M., Iverius, P. H., Hata, A., Wu, L. L., Hillas, E., Williams, R. R., & Lalouel, J. M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114770 · Cited by 165
Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults
Christian, J. B., Bourgeois, N., Snipes, R., & Lowe, K. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.008 · Cited by 159
Apolipoprotein A-V; a potent triglyceride reducer
Nilsson, S. K., Heeren, J., Olivecrona, G., & Merkel, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.019 · Cited by 140
Wang, Q., Wang, G., Qiu, Z., He, X., & Liu, C. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000846 · Cited by 126
Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C‐II
FOJO, S. S., & BREWER, H. B. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb01256.x · Cited by 121
Köbberling Type of Familial Partial Lipodystrophy
Herbst, K. L., Tannock, L. R., Deeb, S. S., Purnell, J. Q., Brunzell, J. D., & Chait, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1819 · Cited by 119
Self-citationMamo, J. C. L., Proctor, S. D., & Smith, D. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00220-2 · Cited by 107
APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency
Calandra, S., Oliva, C. P., Tarugi, P., & Bertolini, S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217892.00618.54 · Cited by 103
Shepherd, J., Betteridge, J., Van Gaal, L., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 101
Gaudet, D., Stroes, E. S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S. J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.158 · Cited by 100
Austin, M. A., & Hokanson, J. E. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30178-x · Cited by 95
Yang, F., Wang, Y., Sternfeld, L., Rodriguez, J. A., Ross, C., Hayden, M. R., Carriere, F., Liu, G., & Schulz, I. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2008.01933.x · Cited by 93
Insulin Therapy for a Non-Diabetic Patient with Severe Hypertriglyceridemia
Jabbar, M. A., Zuhri-Yafi, M. I., & Larrea, J. (1998) · Journal of the American College of Nutrition · doi:10.1080/07315724.1998.10718794 · Cited by 91
Eckel, R. H., Hanson, A. S., Chen, A. Y., Berman, J. N., Yost, T. J., & Brass, E. P. (1992) · Diabetes · doi:10.2337/diab.41.5.641 · Cited by 89
Self-citationDeletion of GPIHBP1 causing severe chylomicronemia
Rios, J. J., Shastry, S., Jasso, J., Hauser, N., Garg, A., Bensadoun, A., Cohen, J. C., & Hobbs, H. H. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9406-5 · Cited by 89
Rahalkar, A. R., Giffen, F., Har, B., Ho, J., Morrison, K. M., Hill, J., Wang, J., Hegele, R. A., & Joy, T. (2009) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-005 · Cited by 86
Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin
Mikhail, N. E., Trivedi, K., Page, C., Wali, S., & Cope, D. (2005) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2005.02.036 · Cited by 84
Chylomicronemia Syndrome in Diabetes Mellitus
Chait, A., Robertson, H. T., & Brunzell, J. D. (1981) · Diabetes Care · doi:10.2337/diacare.4.3.343 · Cited by 83
Self-citationTreatment of hypertriglyceridemia-induced acute pancreatitis with insulin
Coskun, A. K., Erkan, N., Yakan, S., Yıldırım, M., Cartı, E. B., Ucar, D., & Oymacı, E. (2015) · Gastroenterology Review · doi:10.5114/pg.2014.45412 · Cited by 80
Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome
Guillín‐Amarelle, C., Sánchez‐Iglesias, S., Castro-Pais, A. I., Rodríguez‐Cañete, L., Mayán, L. O., Pazos-Couselo, M., González‐Méndez, B., Rodríguez‐García, S., Casanueva, F. F., Marmiesse, A. F., et al. (2016) · Endocrine · doi:10.1007/s12020-016-1002-x · Cited by 79
Kroupa, O., Vorrsjö, E., Stienstra, R., Mattijssen, F., Nilsson, S. K., Sukonina, V., Kersten, S., Olivecrona, G., & Olivecrona, T. (2012) · BMC Physiology · doi:10.1186/1472-6793-12-13 · Cited by 73
Genotype-phenotype relationships in patients with type I hyperlipoproteinemia
Chokshi, N., Blumenschein, S. D., Ahmad, Z., & Garg, A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.006 · Cited by 69
Severe hypertriglyceridemia: role of familial and acquired disorders.
Chait, A., & Brunzell, J. D. (1983) · Metabolism · doi:10.1016/0026-0495(83)90184-1 · Cited by 69
Self-citationShimamura, M., Matsuda, M., Ando, Y., Koishi, R., Yasumo, H., Furukawa, H., & Shimomura, I. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.024 · Cited by 67
Rashid, N., Sharma, P. P., Scott, R. D., Lin, K. J., & Toth, P. P. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.019 · Cited by 66
Berger F, Z., Quera P, R., Poniachik T, J., Oksenberg R, D., & Guerrero P, J. (2001) · Revista médica de Chile · doi:10.4067/s0034-98872001001200002 · Cited by 65
Plasmapheresis as an Adjuvant Therapy for Hypertriglyceridemia-Induced Pancreatitis
Iskandar, S. B., & Olive, K. E. (2004) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200411000-00010 · Cited by 62
Beigneux, A. P., Davies, B. S. J., Bensadoun, A., Fong, L. G., & Young, S. G. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800030-jlr200 · Cited by 59
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study
Davidson, M., Stevenson, M., Hsieh, A., Ahmad, Z., Crowson, C., & Witztum, J. L. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1311786 · Cited by 54
Syed, H., Bilusic, M., Rhondla, C., & Tavaria, A. (2010) · Journal of Clinical Apheresis · doi:10.1002/jca.20232 · Cited by 53
Time trends in incidence, etiology, and case fatality rate of the first attack of acute pancreatitis
Omdal, T., Dale, J., Lie, S. A., Iversen, K., Flaatten, H. K., & Øvrebø, K. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.605464 · Cited by 50
Chaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 46
Heparin and Insulin for Hypertriglyceridemia-Induced Pancreatitis: Case Report
Jain, D. K., & Zimmerschied, J. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.142 · Cited by 45
Controversies in the Etiologies of Acute Pancreatitis
Khan, A., Latif, S. U., & Eloubeidi, M. A. (2015) · PubMed · doi:10.6092/1590-8577/3396 · Cited by 43
Extreme hypertriglyceridemia managed with insulin
Thuzar, M., Shenoy, V. V., Malabu, U. H., Schrale, R. G., & Sangla, K. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.004 · Cited by 42
Sanada, M., Tsuda, M., Kodama, I., Sakashita, T., Nakagawa, H., & Ohama, K. (2004) · Menopause · doi:10.1097/01.gme.0000094211.15096.b4 · Cited by 40
Routy, J., Smith, G. H. R., Blank, D. W., & Gilfix, B. M. (2001) · Journal of Clinical Apheresis · doi:10.1002/jca.1030 · Cited by 37
Izumi, R., Kusakabe, T., Noguchi, M., Iwakura, H., Tanaka, T., Miyazawa, T., Aotani, D., Hosoda, K., Kangawa, K., & Nakao, K. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m082099 · Cited by 37
Zafrir, B., Jubran, A., Hijazi, R., & Shapira, C. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.086 · Cited by 31
Ciudin, A., Baena‐Fustegueras, J. A., Fort, J. M., Encabo, G., Mesa, J., & Lecube, A. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04057.x · Cited by 29
Effectiveness of Gastric Bypass Surgery in a Patient With Familial Partial Lipodystrophy
Utzschneider, K. M., & Trence, D. (2006) · Diabetes Care · doi:10.2337/dc06-0130 · Cited by 29
Pedersen, S. B., Varbo, A., Langsted, A., & Nordestgaard, B. G. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12713 · Cited by 29
Jackson, K. G., Robertson, M. D., Fielding, B. A., Frayn, K. N., & Williams, C. M. (2002) · Clinical Science · doi:10.1042/cs1030227 · Cited by 28
Plasmapheresis in the Treatment of Hypertriglyceridemic Pancreatitis with ARDS
Kohli, R. S., Bleibel, W., Shetty, A. K., & Dhanjal, U. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9315-x · Cited by 28
Hemelaar, M., van der Mooren, M. J., Mijatovic, V., Bouman, A. A., Schijf, C. P. T., Kroeks, M. V. A. M., Franke, H. R., & Kenemans, P. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000064866.58809.e5 · Cited by 27
Safety considerations with fenofibrate/simvastatin combination
Filippatos, T. D., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056778 · Cited by 24
Acute pancreatitis owing to very high triglyceride levels treated with insulin and heparin infusion
Aryal, M. R., Mainali, N. R., Gupta, S., & Singla, M. (2013) · BMJ Case Reports · doi:10.1136/bcr-2013-008550 · Cited by 19
Brown, W. V., Brunzell, J. D., Eckel, R. H., & Stone, N. J. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.08.002 · Cited by 19
Self-citationPresentation and management of acute hypertriglyceridemic pancreatitis in pregnancy: A case report
Lim, R., Rodger, S. J., & Hawkins, T. L. (2015) · Obstetric Medicine · doi:10.1177/1753495x15605697 · Cited by 13
Kido, K., Evans, R. A., Gopinath, A., & Flynn, J. D. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017692920 · Cited by 11
Treatment of hypertriglyceridemia
Capell, W. H., & Eckel, R. H. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0040-9 · Cited by 10
Self-citationIdentificación de variantes en el gen LMF1 asociadas con hipertrigliceridemia primaria
Lamíquiz-Moneo, I., Bea, A. M., Mateo‐Gállego, R., Baila-Rueda, L., Cenarro, A., Pocoví, M., Civeira, F., & de Castro-Orós, I. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.02.005 · Cited by 6
Williams, S., Green, R., Morrison, A., Watson, D. I., & Buchanan, S. (2006) · Journal of Clinical Apheresis · doi:10.1002/(issn)1098-1101 · Cited by 4
Research works printed but not linked: 3
- Fortson MR, 1995, Am J Gastroenterol, 90, 2134
- Ranson JH, 1974, Surg Gynecol Obstet, 139, 69
- Khan AS, 2010, JOP, 11, 545
Cited by
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“6,14,29,30 While TG >10mmol/L (885mg/dL) may be sufficient to precipitate acute pancreatitis without additional factors, in many patients, especially those experiencing pancreatitis at relatively low TG levels, additional factors such as alcohol consumption, gallstone disease or certain medications…”
BackgroundVirani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Genetics of hypertriglyceridemia
Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Metadata
- Authors
- Chait, A., & Eckel, R. H.
- Affiliations
- University of Washington (US)
- University of Colorado Anschutz (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-05-07
- Volume
- 170
- Issue
- 9
- Pages
- 626-634
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2942839572
- Cited by
- 128
- References
- 94
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 16 · 2023: 12 · 2022: 25 · 2021: 12 · 2020: 27 · 2019: 4
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- chylomicronemia syndrome, hypertriglyceridemia, familial chylomicronemia syndrome, familial partial lipodystrophy, lipoprotein lipase deficiency, triglyceride-rich lipoproteins, lipoprotein clearance, eruptive xanthoma, lipemia retinalis, acute pancreatitis, treatment options
- MeSH terms
- Algorithms, Hypolipidemic Agents, Apolipoproteins, Cardiovascular Diseases, Chylomicrons, Humans, Lipoprotein Lipase, Hyperlipoproteinemia Type I, Mutation, Oligonucleotides, Pancreatitis, Risk Factors, Hypertriglyceridemia, Fatty Acids, Omega-3, Receptors, Lipoprotein, Genetic Predisposition to Disease, Angiopoietins, Lipodystrophy, Familial Partial, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.